Cargando…

Nrf2 activator PB125® as a carnosic acid-based therapeutic agent against respiratory viral diseases, including COVID-19()

PB125® is a phytochemical composition providing potent Nrf2 activation as well as a number of direct actions that do not involve Nrf2. Nrf2 is a transcription actor that helps maintain metabolic balance by providing redox-sensitive expression of numerous genes controlling normal day-to-day metabolic...

Descripción completa

Detalles Bibliográficos
Autores principales: McCord, Joe M., Hybertson, Brooks M., Cota-Gomez, Adela, Gao, Bifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413148/
https://www.ncbi.nlm.nih.gov/pubmed/34058321
http://dx.doi.org/10.1016/j.freeradbiomed.2021.05.033
_version_ 1783747600649814016
author McCord, Joe M.
Hybertson, Brooks M.
Cota-Gomez, Adela
Gao, Bifeng
author_facet McCord, Joe M.
Hybertson, Brooks M.
Cota-Gomez, Adela
Gao, Bifeng
author_sort McCord, Joe M.
collection PubMed
description PB125® is a phytochemical composition providing potent Nrf2 activation as well as a number of direct actions that do not involve Nrf2. Nrf2 is a transcription actor that helps maintain metabolic balance by providing redox-sensitive expression of numerous genes controlling normal day-to-day metabolic pathways. When ordinary metabolism is upset by extraordinary events such as injury, pathogenic infection, air or water pollution, ingestion of toxins, or simply by the slow but incessant changes brought about by aging and genetic variations, Nrf2 may also be called into action by the redox changes resulting from these events, whether acute or chronic. A complicating factor in all of this is that Nrf2 levels decline with aging, leaving the elderly less able to maintain proper redox balance. The dysregulated gene expression that results can cause or exacerbate a wide variety of pathological conditions, including susceptibility to viral infections. This review examines the characteristics desirable in Nrf2 activators that have therapeutic potential, as well as some of the patterns of dysregulated gene expression commonly observed during pulmonary infections and the normalizing effects possible by judicious use of phytochemicals to increase the activation level of available Nrf2.
format Online
Article
Text
id pubmed-8413148
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-84131482021-09-03 Nrf2 activator PB125® as a carnosic acid-based therapeutic agent against respiratory viral diseases, including COVID-19() McCord, Joe M. Hybertson, Brooks M. Cota-Gomez, Adela Gao, Bifeng Free Radic Biol Med Invited Review Article PB125® is a phytochemical composition providing potent Nrf2 activation as well as a number of direct actions that do not involve Nrf2. Nrf2 is a transcription actor that helps maintain metabolic balance by providing redox-sensitive expression of numerous genes controlling normal day-to-day metabolic pathways. When ordinary metabolism is upset by extraordinary events such as injury, pathogenic infection, air or water pollution, ingestion of toxins, or simply by the slow but incessant changes brought about by aging and genetic variations, Nrf2 may also be called into action by the redox changes resulting from these events, whether acute or chronic. A complicating factor in all of this is that Nrf2 levels decline with aging, leaving the elderly less able to maintain proper redox balance. The dysregulated gene expression that results can cause or exacerbate a wide variety of pathological conditions, including susceptibility to viral infections. This review examines the characteristics desirable in Nrf2 activators that have therapeutic potential, as well as some of the patterns of dysregulated gene expression commonly observed during pulmonary infections and the normalizing effects possible by judicious use of phytochemicals to increase the activation level of available Nrf2. Published by Elsevier Inc. 2021-11-01 2021-05-28 /pmc/articles/PMC8413148/ /pubmed/34058321 http://dx.doi.org/10.1016/j.freeradbiomed.2021.05.033 Text en © 2021 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Invited Review Article
McCord, Joe M.
Hybertson, Brooks M.
Cota-Gomez, Adela
Gao, Bifeng
Nrf2 activator PB125® as a carnosic acid-based therapeutic agent against respiratory viral diseases, including COVID-19()
title Nrf2 activator PB125® as a carnosic acid-based therapeutic agent against respiratory viral diseases, including COVID-19()
title_full Nrf2 activator PB125® as a carnosic acid-based therapeutic agent against respiratory viral diseases, including COVID-19()
title_fullStr Nrf2 activator PB125® as a carnosic acid-based therapeutic agent against respiratory viral diseases, including COVID-19()
title_full_unstemmed Nrf2 activator PB125® as a carnosic acid-based therapeutic agent against respiratory viral diseases, including COVID-19()
title_short Nrf2 activator PB125® as a carnosic acid-based therapeutic agent against respiratory viral diseases, including COVID-19()
title_sort nrf2 activator pb125® as a carnosic acid-based therapeutic agent against respiratory viral diseases, including covid-19()
topic Invited Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413148/
https://www.ncbi.nlm.nih.gov/pubmed/34058321
http://dx.doi.org/10.1016/j.freeradbiomed.2021.05.033
work_keys_str_mv AT mccordjoem nrf2activatorpb125asacarnosicacidbasedtherapeuticagentagainstrespiratoryviraldiseasesincludingcovid19
AT hybertsonbrooksm nrf2activatorpb125asacarnosicacidbasedtherapeuticagentagainstrespiratoryviraldiseasesincludingcovid19
AT cotagomezadela nrf2activatorpb125asacarnosicacidbasedtherapeuticagentagainstrespiratoryviraldiseasesincludingcovid19
AT gaobifeng nrf2activatorpb125asacarnosicacidbasedtherapeuticagentagainstrespiratoryviraldiseasesincludingcovid19